Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of celiac disease for each…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the total and diagnosed prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key celiac disease patient populations, covering 171 countries and more…

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD), is a genetic disorder in which fluid-filled cysts progressively develop in the kidney…

Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico…

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF…

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX (FIX). Individuals with this condition experience prolonged bleeding. Prescribing options include factor balancing…

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute heart failure (AHF) patient populations, covering 171…

Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India,…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic heart failure (CHF) patient populations, covering 171…

Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…